Anti-TNF? antibody data

Results of an open Phase I/II trial in 20 patients treated with 20 mg/kg of the Malvern, Penn., company's antibody showed no adverse effects and significant improvement in symptoms.

As published in Arthritis & Rheumatism, the swollen joint count fell from 18 to 5 in these patients (p < 0.001) and another index of symptoms showed a fall from a median of 28 to 6 by week six of the eight-week study (p < 0.001). ...